ONC Stock BeOne Medicines (ONC, $360.85) entered a monthly bullish trend. Expect an Uptrend continuation
at Tickeron.com
Loading...
BeOne Medicines Ltd (ONC, $360.85) is predicted by A.I.dvisor to grow by to $375.28 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are
ONC sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ONC moved above the 200-day moving average on August 25, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on ONC as a result. In 61 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ONC just turned positive on September 23, 2026. Looking at past instances where ONC's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in 224 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ONC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 180 of 244 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The 10-day RSI Indicator for ONC moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 21 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ONC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 57 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.886) is normal, around the industry mean (26.565). P/E Ratio (64.553) is within average values for comparable stocks, (41.388). Projected Growth (PEG Ratio) (0.763) is also within normal values, averaging (9.024). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.